pioglitazone has been researched along with Chronic Hepatitis C in 11 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
Excerpt | Relevance | Reference |
---|---|---|
"Insulin resistance (IR) affects sustained virological response (SVR) to peginterferon alfa plus ribavirin (PR) in patients with chronic hepatitis C (CHC)." | 9.19 | A pilot study of add-on oral hypoglycemic agents in treatment-naïve genotype-1 chronic hepatitis C patients receiving peginterferon alfa-2b plus ribavirin. ( Chen, DS; Hsu, CS; Hsu, SJ; Kao, JH; Lin, HH; Tseng, TC; Wang, CC, 2014) |
"Treatment with pioglitazone before and during treatment with peginterferon alpha-2a plus ribavirin improved several indices of glycemic control in patients with chronic hepatitis C and insulin resistance, but did not improve virologic response rates compared with peginterferon alpha-2a plus ribavirin alone." | 9.16 | Chronic hepatitis C genotype 1 patients with insulin resistance treated with pioglitazone and peginterferon alpha-2a plus ribavirin. ( Hamzeh, FM; Han, J; Harrison, SA; Pandya, PK; Sheikh, MY; Vierling, JM, 2012) |
" The safety and efficacy of pioglitazone on insulin sensitivity and SVR in treatment-naïve patients with chronic hepatitis C (CHC) genotype 4 with IR receiving standard antiviral therapy were evaluated in a randomized-controlled study." | 9.14 | Pioglitazone improves virological response to peginterferon alpha-2b/ribavirin combination therapy in hepatitis C genotype 4 patients with insulin resistance. ( Abdelaleem, A; Atef, R; Emad, M; Eslam, M; Hamdy, L; Khattab, M; Shaker, Y, 2010) |
"We started a multicenter clinical trial of retreatment of chronic hepatitis C patients, who had failed to respond to the pegylated interferon alfa/ribavirin combination, with a triple therapy consisting in these same antivirals plus an insulin-sensitizer (pioglitazone) (The INSPIRED-HCV study)." | 9.13 | Pioglitazone in chronic hepatitis C not responding to pegylated interferon-alpha and ribavirin. ( Genné, D; Golay, A; Negro, F; Overbeck, K, 2008) |
"To compare metformin and pioglitazone with standard interferon and ribavirin in achieving sustained virological response in chronic hepatitis C patients." | 7.85 | Comparison of metformin and pioglitazone in achieving sustained virological response in chronic hepatitis C patients with insulin resistance: A quasi-experimental study. ( Butt, NF; Hamid, S; Khan, IM; Malik, BR; Malik, U; Randhawa, FA, 2017) |
"Pioglitazone was well tolerated and no one discontinued due to side effects." | 6.80 | Pioglitazone for Hepatic Steatosis in HIV/Hepatitis C Virus Coinfection. ( Benator, D; Chairez, C; Hadigan, C; Kleiner, DE; Kovacs, JA; Matthews, L; McManus, M; Morse, CG; Nettles, MJ; Zemanick, K, 2015) |
": Insulin resistance is associated with nonresponse to hepatitis C virus (HCV) treatment." | 6.79 | Pilot study of pioglitazone before HCV retreatment in HIV/HCV genotype 1-infected subjects with insulin resistance and previous nonresponse to peginterferon and ribavirin therapy: A5239. ( Alston-Smith, B; Andersen, J; Chung, RT; Glesby, MJ; Hadigan, C; Kitch, D; Luetkemeyer, A; Marks, KM; Tien, P, 2014) |
"Pioglitazone was effective in decreasing serum HCV RNA at day-14 (n = 10; difference of means = 205,618 IU/ml; 95% CI 26,600 to 384,600; P<0." | 6.77 | Pioglitazone decreases hepatitis C viral load in overweight, treatment naïve, genotype 4 infected-patients: a pilot study. ( Buck, M; Chojkier, M; Donohue, M; Elkhayat, H; Sabry, D, 2012) |
"Insulin resistance (IR) affects sustained virological response (SVR) to peginterferon alfa plus ribavirin (PR) in patients with chronic hepatitis C (CHC)." | 5.19 | A pilot study of add-on oral hypoglycemic agents in treatment-naïve genotype-1 chronic hepatitis C patients receiving peginterferon alfa-2b plus ribavirin. ( Chen, DS; Hsu, CS; Hsu, SJ; Kao, JH; Lin, HH; Tseng, TC; Wang, CC, 2014) |
"Treatment with pioglitazone before and during treatment with peginterferon alpha-2a plus ribavirin improved several indices of glycemic control in patients with chronic hepatitis C and insulin resistance, but did not improve virologic response rates compared with peginterferon alpha-2a plus ribavirin alone." | 5.16 | Chronic hepatitis C genotype 1 patients with insulin resistance treated with pioglitazone and peginterferon alpha-2a plus ribavirin. ( Hamzeh, FM; Han, J; Harrison, SA; Pandya, PK; Sheikh, MY; Vierling, JM, 2012) |
" The safety and efficacy of pioglitazone on insulin sensitivity and SVR in treatment-naïve patients with chronic hepatitis C (CHC) genotype 4 with IR receiving standard antiviral therapy were evaluated in a randomized-controlled study." | 5.14 | Pioglitazone improves virological response to peginterferon alpha-2b/ribavirin combination therapy in hepatitis C genotype 4 patients with insulin resistance. ( Abdelaleem, A; Atef, R; Emad, M; Eslam, M; Hamdy, L; Khattab, M; Shaker, Y, 2010) |
"We started a multicenter clinical trial of retreatment of chronic hepatitis C patients, who had failed to respond to the pegylated interferon alfa/ribavirin combination, with a triple therapy consisting in these same antivirals plus an insulin-sensitizer (pioglitazone) (The INSPIRED-HCV study)." | 5.13 | Pioglitazone in chronic hepatitis C not responding to pegylated interferon-alpha and ribavirin. ( Genné, D; Golay, A; Negro, F; Overbeck, K, 2008) |
"To compare metformin and pioglitazone with standard interferon and ribavirin in achieving sustained virological response in chronic hepatitis C patients." | 3.85 | Comparison of metformin and pioglitazone in achieving sustained virological response in chronic hepatitis C patients with insulin resistance: A quasi-experimental study. ( Butt, NF; Hamid, S; Khan, IM; Malik, BR; Malik, U; Randhawa, FA, 2017) |
"Pioglitazone was well tolerated and no one discontinued due to side effects." | 2.80 | Pioglitazone for Hepatic Steatosis in HIV/Hepatitis C Virus Coinfection. ( Benator, D; Chairez, C; Hadigan, C; Kleiner, DE; Kovacs, JA; Matthews, L; McManus, M; Morse, CG; Nettles, MJ; Zemanick, K, 2015) |
": Insulin resistance is associated with nonresponse to hepatitis C virus (HCV) treatment." | 2.79 | Pilot study of pioglitazone before HCV retreatment in HIV/HCV genotype 1-infected subjects with insulin resistance and previous nonresponse to peginterferon and ribavirin therapy: A5239. ( Alston-Smith, B; Andersen, J; Chung, RT; Glesby, MJ; Hadigan, C; Kitch, D; Luetkemeyer, A; Marks, KM; Tien, P, 2014) |
"Pioglitazone was effective in decreasing serum HCV RNA at day-14 (n = 10; difference of means = 205,618 IU/ml; 95% CI 26,600 to 384,600; P<0." | 2.77 | Pioglitazone decreases hepatitis C viral load in overweight, treatment naïve, genotype 4 infected-patients: a pilot study. ( Buck, M; Chojkier, M; Donohue, M; Elkhayat, H; Sabry, D, 2012) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 3 (27.27) | 29.6817 |
2010's | 8 (72.73) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Khan, IM | 1 |
Malik, BR | 1 |
Randhawa, FA | 1 |
Butt, NF | 1 |
Malik, U | 1 |
Hamid, S | 1 |
Ullman, K | 1 |
Marks, KM | 1 |
Kitch, D | 1 |
Chung, RT | 1 |
Hadigan, C | 2 |
Andersen, J | 1 |
Tien, P | 1 |
Luetkemeyer, A | 1 |
Alston-Smith, B | 1 |
Glesby, MJ | 1 |
Hsu, CS | 1 |
Hsu, SJ | 1 |
Lin, HH | 1 |
Tseng, TC | 1 |
Wang, CC | 1 |
Chen, DS | 1 |
Kao, JH | 1 |
Matthews, L | 1 |
Kleiner, DE | 1 |
Chairez, C | 1 |
McManus, M | 1 |
Nettles, MJ | 1 |
Zemanick, K | 1 |
Morse, CG | 1 |
Benator, D | 1 |
Kovacs, JA | 1 |
Overbeck, K | 1 |
Genné, D | 1 |
Golay, A | 1 |
Negro, F | 1 |
Serfaty, L | 1 |
Fartoux, L | 1 |
Poupon, R | 1 |
Khattab, M | 1 |
Emad, M | 1 |
Abdelaleem, A | 1 |
Eslam, M | 1 |
Atef, R | 1 |
Shaker, Y | 1 |
Hamdy, L | 1 |
Harrison, SA | 1 |
Hamzeh, FM | 1 |
Han, J | 1 |
Pandya, PK | 1 |
Sheikh, MY | 1 |
Vierling, JM | 1 |
Chojkier, M | 1 |
Elkhayat, H | 1 |
Sabry, D | 1 |
Donohue, M | 1 |
Buck, M | 1 |
Füessl, HS | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Metformin as Adjunctive Therapy in Overweight and Obese Patients With Dengue: an Open-label Safety and Tolerability Trial[NCT04377451] | Phase 1/Phase 2 | 120 participants (Actual) | Interventional | 2020-07-27 | Completed | ||
Pioglitazone for Hepatic Steatosis in HIV/HCV Co-infection[NCT00742326] | Phase 4 | 13 participants (Actual) | Interventional | 2008-08-31 | Terminated (stopped due to Enrollment stopped prior to complete enrollment due to slow accrual) | ||
A Randomized, Partially Blinded, Pilot Study of the Effects of Pioglitazone on HCV RNA in Overweight Subjects With Chronic HCV Genotypes 1 or 4 Infection.[NCT01157975] | Phase 2 | 0 participants (Actual) | Interventional | 2008-10-31 | Withdrawn (stopped due to Study was completed in another site) | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Change in hepatic steatosis and hepatic inflammation/fibrosis in HIV/HCV co-infected patients with steatosis. Change in Hepatic Fat Content measured by MR spectroscopy: 48 weeks compared to Baseline (NCT00742326)
Timeframe: 48 weeks
Intervention | percentage of hepatic fat on MRS (Mean) |
---|---|
Pioglitazone | -7.43 |
Placebo | -2.17 |
Change in Glucose Area Under the Curve from standard oral glucose challenge ( baseline to 2 hours): Week 48 - Baseline values (NCT00742326)
Timeframe: 48 weeks
Intervention | mg*120 minutes/dL (Mean) |
---|---|
Pioglitazone | -31 |
Placebo | 11 |
7 trials available for pioglitazone and Chronic Hepatitis C
Article | Year |
---|---|
Pilot study of pioglitazone before HCV retreatment in HIV/HCV genotype 1-infected subjects with insulin resistance and previous nonresponse to peginterferon and ribavirin therapy: A5239.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; Female; Genotype; Hepaci | 2014 |
A pilot study of add-on oral hypoglycemic agents in treatment-naïve genotype-1 chronic hepatitis C patients receiving peginterferon alfa-2b plus ribavirin.
Topics: Acarbose; Adult; Aged; Antiviral Agents; Drug Resistance, Multiple, Viral; Drug Therapy, Combination | 2014 |
Pioglitazone for Hepatic Steatosis in HIV/Hepatitis C Virus Coinfection.
Topics: Adult; Coinfection; Double-Blind Method; Fatty Liver; Female; Hepatitis C, Chronic; Histocytochemist | 2015 |
Pioglitazone in chronic hepatitis C not responding to pegylated interferon-alpha and ribavirin.
Topics: Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepatitis C, Chronic; H | 2008 |
Pioglitazone improves virological response to peginterferon alpha-2b/ribavirin combination therapy in hepatitis C genotype 4 patients with insulin resistance.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chro | 2010 |
Chronic hepatitis C genotype 1 patients with insulin resistance treated with pioglitazone and peginterferon alpha-2a plus ribavirin.
Topics: Adult; Antiviral Agents; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Stu | 2012 |
Pioglitazone decreases hepatitis C viral load in overweight, treatment naïve, genotype 4 infected-patients: a pilot study.
Topics: Adult; Antiviral Agents; Blood Glucose; Chemical and Drug Induced Liver Injury; Cytokines; Female; G | 2012 |
4 other studies available for pioglitazone and Chronic Hepatitis C
Article | Year |
---|---|
Comparison of metformin and pioglitazone in achieving sustained virological response in chronic hepatitis C patients with insulin resistance: A quasi-experimental study.
Topics: Adult; Antiviral Agents; Blood Glucose; Female; Hepatitis C, Chronic; Humans; Hypoglycemic Agents; I | 2017 |
THE HEPATITIS/DIABETES CONNECTION The Effect of Hep C cures on Type 2 diabetes still unknown.
Topics: Antiviral Agents; Comorbidity; Diabetes Mellitus, Type 2; Hepatitis B; Hepatitis B Vaccines; Hepatit | 2016 |
Pioglitazone as adjuvant therapy in chronic hepatitis C: sequential rather than concomitant administration with pegylated interferon and ribavirin?
Topics: Adult; Antiviral Agents; Chemotherapy, Adjuvant; Drug Administration Schedule; Hepatitis C, Chronic; | 2009 |
[Fatty liver. Not only ultrasound to be relied on!].
Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; Fatty Liver; Female; Hepatitis; Hepatitis C; Hep | 2003 |